BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Overview: Avmapki Fakzynja Co-Pack is used to treat ovarian cancer in certain people. It contains two medicines that work together to slow the growth of cancer cells. The most common side effects are ...
LOUISVILLE, Ky., May 12, 2025 (GLOBE NEWSWIRE) -- Onco360 ®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem Oncology for AVMAPKI ™ ...
Avmapki Fakzynja is a type of targeted medicine called a tyrosine kinase inhibitor (TKI). TKIs are used to treat many different types of cancers, including ovarian cancer. Avmapki Fakzynja is ...
The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. The FDA has ...
AVMAPKI plus FAKZYNJA to be commercially available by prescription as a convenient oral combination co-packaged together and will be known as “AVMAPKI FAKZYNJA CO-PACK” Accelerated approval, well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback